Accelerating discovery with greater visibility
Development of safe and effective immunotherapies through use of multidimensional data
The current approaches to drug discovery and development are often based on single-point data, such as genomic markers or linear approaches. Javelin incorporates additional patient-specific data, including tumor-specific gene expression data, molecular libraries, and therapeutic modalities, to assist in prediction of successful therapeutic interventions. Utilizing our unique multidimensional approach radically enhances targeting as well as minimizing the time and costs of the therapeutic development process.
OUR METHODOLOGY FOCUSES ON:
- Target selection – known and novel immuno-oncology target discovery
- Therapy selection – selecting the right therapeutic modality
- Patient selection – identifying smaller cohorts based on predicting the desired efficacy and safety responses
REDUCE TIME AND COST OF CLINICAL TRIALS
Testing new therapeutic targets requires significant time and resources. Javelin can help reduce the time and cost of trials by selecting participants that are most likely to respond to treatment. We do this by integrating unique patient data, molecular libraries and modality or therapy choice to optimize treatment selection for specific patient groups, which can reduce development time and costs by up to 90%.
Development time and costs
Learn more about how the Javelin Oncology platform integrates multidimensional data and sophisticated prediction methods to enhance identification, stratification and predictive capabilities around personalized immunotherapies
Learn how we use multidimensional data to inform target design
Using our proprietary models and algorithms to predict clinical response rates
Versatile platform shared with others to advance and accelerate their immuno-oncology applications